Brandon Hayes-Lattin, M.D., FACP

  • Professor of Medicine, School of Medicine


Dr. Brandon Hayes-Lattin serves as Professor of Medicine and Medical Director in the Division of Hematology and Medical Oncology at Oregon Health and Science University, and Medical Director of the OHSU Knight Cancer Institute’s Adolescent and Young Adult (AYA) Oncology Program. His clinical background is in the management of hematologic malignancies and the use of hematopoietic stem cell transplantation. As a young adult cancer survivor himself, and a physician caring for many young adults with hematologic malignancies, Dr. Hayes-Lattin has taken a leadership role in the development of the discipline of AYA Oncology. He has served as the Senior Medical Advisor to the LIVESTRONG Foundation, the Chief Medical Officer for Critical Mass: The Young Adult Cancer Alliance, the inaugural Chair of the AYA Committee for SWOG, participated on the expert advisory panel to the Children’s Oncology Group AYA Committee, and was a member of the CDC’s Federal Advisory Committee on Breast Cancer in Young Women.


  • B.S., 1992, Stanford University
  • M.D., 1997, University of Washington
  • Residency:

    • Internal Medicine, Oregon Health & Science University, Portland, OR 2000
  • Fellowship:

    • Bone Marrow Transplantation, Oregon Health & Science University, Portland, OR 2001
    • Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 2004
  • Certifications:

    • American Board of Internal Medicine, Hematology recertification, 2016

Honors and awards

  • Oncology Professional Award, The Ulman Cancer Fund for Young Adults
  • Faculty Award, The OHSU Student Council
  • Teaching Certificate of Appreciation, Division of Physician Assistant Education
  • Medical House Staff Teaching Award
  • John S. Miller Award for Outstanding Teaching

Memberships and associations

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American College of Physicians
  • American Society for Transplantation and Cellular Therapy

Areas of interest

  • Acute Lymphoblastic Leukemia
  • CAR-T therapy


Elsevier pure profile


  • {{[0].value }}